In BLCA, METTL16 reduces the stability of prostate transmembrane protein androgen-induced 1 (PMEPA1) mRNA, inhibiting cell proliferation and cisplatin chemoresistance, thus offering a potential therapeutic strategy for BLCA (143). The gene discussed is PMEPA1; the disease is bladder transitional cell carcinoma.